Human hepatocellular carcinoma (HCC) is one of the leading causes for mortality in the world and there is no effective chemotherapy at present. Therefore, development of new therapeutically effective and low toxic reagents, particularly injectable drugs, will be of great significance. ZCVI 4 -2 ( Fig. 1 ) is a newly developed furoxan-based nitric oxide-releasing derivative of oleanolic acid, and has been successfully synthesized as galactosyl derivative 3 of the compound 1 (furoxan-based nitric oxide-releasing derivative of oleanolic acid) by Huang et al. 1) As reported previously, it exhibited strong cytotoxicity against HCC in vitro and significantly inhibited the growth of HCC tumors in vivo, indicating that ZCVI 4 -2 may be a promising candidate for the treatment of human HCC. 1) However, ZCVI 4 -2 has a very low aqueous solubility (Ͻ10 mg/ml at pH 3.0-9.0). The poor solubility of ZCVI 4 -2 has been a major hindrance in the development of its parenteral dosage forms. In our previous research, the combination of macrogol 15 hydroxystearate (Solutol HS-15), propylene glycol and ethanol was used to improve its solubility successfully to be up to 5 mg/ml. In vivo activity evaluation indicated that ZCVI 4 -2 treatment with 25 mg/kg of ZCVI 4 -2 enhanced the inhibitory effect on the growth of HCC tumors SMMC-7721 transplanted in nude mice ( pϽ0.01 vs. treatment with 12.5 mg/kg), and its inhibitory effect was similar to that of 5-FU treatment. The tumor weights in the mice treated with ZCVI 4 -2 at 12.5 or 25 mg/kg was significantly lower than that from the vehicletreated controls (pϽ0.01). However, ZCVI 4 -2 injection displayed obvious toxicity to mice in toxicological studies with a LD 50 value of 94.1 mg/kg. 1) By comparing the mice survival of ZCVI 4 -2 suspension with ZCVI 4 -2 injection, it was inferred that the toxicity of ZCVI 4 -2 may be attributed firstly to the fast release of nitric oxide (NO) in blood and secondly to the surfactant and organic solvents in the formulation.
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The serum albumin was used frequently for the preparation of nanoparticles because of its excellent water-solubility and biocompatibility. Human serum albumin (HSA) had been successfully bound with paclitaxel and formulated into Abraxane ® , the paclitaxel protein-bound particles for injectable suspension. The absence of organic solvents and surfactants significantly improved the clinical safety. [2] [3] [4] [5] The key step to prepare the protein (bovine serum albumin (BSA) or HSA)-bound nanocomplex is to determine the rational condition for the binding between drug and protein through interaction study. To date, however, the interaction characteristics, the binding condition for paclitaxel and HSA, the screening process of formulation and technology of Abraxane ® were not reported. To delay the release of the NO, and to lower the toxicity after injection, the serum albumin (BSA) was utilized for the preparation of the surfactant-free serum albumin nanocomplexes of ZCVI 4 -2 in this study. The main objective of the present study is to study the interaction characteristics between ZCVI 4 -2 and BSA and then to determine the preparation parameters of ZCVI 4 -2 BSA-bound injectable nanocomplexes. Moreover, the NO release characteristics of ZCVI 4 -2/BSA nanocomplexes were also studied to reveal the influence of serum albumin nanocomplexes.
Experimental
Materials Albumin Bovine V was purchased from Sigma, U.S.A. ZCVI 4 -2 was synthesized by Center of Drug Discovery of China Pharmaceutical University (Nanjing, China). Sodium Nitrite was purchased from Shanghai Sino Fine Chemical Co., Ltd. (Shanghai, China). N-1-Napthylethylenediamine dihydrochloride and sulfanilamide were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). L-Cysteine was purchased from HuaXing Biochemistry Reagent Co., Ltd. (Menzhou, China). Other chemicals were of HPLC or analytical grade.
Methods. The Quenching of Intrinsic Fluorescence of BSA by ZCVI 4 -2 ZCVI 4 -2 solutions with concentrations from 0 to 100 mg/ml at an interval of 20 mg/ml were prepared as control groups by dissolving ZCVI 4 -2 in ethanol and subsequent dilution. Fluorescence scanning of these solutions was conducted at the excitation wavelength of 280 nm, the emission spectra of 250-400 nm were recorded to examine whether the drug and ethanol emit fluorescence when excited by UV light. ZCVI 4 -2 solutions with concentrations from 0 to 100 mg/ml at an interval of 20 mg/ml were prepared by diluting ZCVI 4 -2 ethanol solution (4.0 mg/ml) in two phosphate buffers (pH 3.0 and pH 6.8, 0.01 mol/l); the concentration of BSA in each solution was 0.5 mg/ml. Fluorescence scanning of these samples were carried out at 4°C, 15°C, 22°C and 30°C respectively as described above to evaluate the influence of temperature and pH environment on the quenching of intrinsic BSA fluorescence.
A series of solutions with pH ranging from 2.13 to 11.76 were prepared, and under each pH, the concentrations of ZCVI 4 -2 were from 0 to 100 mg/ml at an interval of 20 mg/ml by diluting ZCVI 4 -2 ethanol solution (4.0 mg/ml) in buffers; the concentrations of BSA in all the solutions were 0.5 mg/ml. Fluorescence scanning of these solutions were conducted were carried out at 30°C as described above to study the effect of pH on the quenching of BSA intrinsic fluorescence.
Synchronous fluorescence spectrometry of BSA was performed to explore the structural change of BSA caused by ZCVI 4 -2. The synchronous fluorescence spectra of these solutions above were obtained by setting Dlϭ15 nm and Dlϭ60 nm, respectively. The excitation and emission slit widths were set at 10.0 nm.
The Quenching Effect of ZCVI 4 -2 on BSA Fluorescence Intensity The classical relationship often employed to describe the collisional quenching process is the Stern-Volmer equation 6, 7) :
(1)
Where F 0 and F are the fluorescence intensity in the absence and presence of quencher (ZCVI 4 -2), K q is the quenching rate constant of the biomacromolecule (BSA), which reflects the influence of diffusion and collision between the biomacromolecule (BSA) and the fluorescence quencher on the decay rate of fluorescence lifetime of biomacromolecule in the system. 7) The maximum dynamic collision quenching constants of various kinds of quenchers are around 2.0ϫ10 10 l Ϫ1 mol Ϫ1 s Ϫ1 for biopolymers fluorescence and 7ϫ10 9 M Ϫ1 s Ϫ1 for protein. 8) t 0 is the lifetime of the fluorescence in the absence of quencher, and for BSA, t 0 is around 10. 8, 9) K sv ϭK q ϫt 0 is the Stern-Volmer quenching constant, K sv indicates the dose-effect relationship between the biomacromolecule (BSA) and fluorescence quencher when the diffusion and collision between them reaches a dynamic equilibrium. 7) [D] is the concentration of the quencher (ZCVI 4 -2).
Herein, Eq. 1 was applied to determine K sv by a linear regression of the plot of F 0 /F against [D] . A linear Stern-Volmer plot is generally indicative of the presence of a single class of fluorophores in a protein, all equally accessibly to the quencher, this also means that only one quenching mechanism (dynamic or static) exists. 10) For static quenching, when small molecules bind independently to a set of equivalent sites on a macromolecule, the equilibrium between free and bound molecules is described by the Scatchard equation or Binding equation, Eq. 2 [11] [12] [13] :
Where K b is the dissociation binding constant which is an indicator of the affinity to the binding site, 13) also reflects the degree of interaction between BSA and ZCVI 4 -2; n is the number of binding sites per albumin molecule, here it refers to the number of ZCVI 4 -2 bound to a BSA macromolecule. 14) According to Eq. 2, binding parameters can be obtained by plotting log(F 0 ϪF)/F versus log[D]. [15] [16] [17] Fluorescence Emission of Control Groups To exclude the influence of ethanol and ZCVI 4 -2 on the fluorescence spectrum of BSA, the fluorescence signals of control groups with ZCVI 4 -2 solution (0-100 mg/ml) and a fixed amount of ethanol were monitored in the tested excitation and emission wavelength. The results showed that the emission of control groups were negligible, thus ethanol and free ZCVI 4 -2 did not affect the fluorescence spectrum of BSA.
The Binding Site Estimation The fluorescence intensity of BSA (F 0 ) and ZCVI 4 -2 (F) solutions was tested in RF-5301PC-Spectrofluorophotometer (Shimadzu Scientific Instruments, Inc., Japan) at an excitation wavelength of 280 nm and an emission wavelength of 388 nm. UV absorption spectrum of ZCVI 4 -2 was obtained by scanning ZCVI 4 -2 solution in a UV spectrophotometer (8453 Visible Spectroscopy, Agilent Technologies, Ltd., U.S.A.) from 300 to 400 nm. Fluorescence emission spectrum of BSA was obtained by fluorescence scanning of BSA solution at an excitation wavelength of 280 nm and emission wavelength of 300-400 nm. The concentrations of BSA and ZCVI 4 -2 solutions were both 7.4ϫ10
Ϫ6 mol/l. F 0 , F, UV absorption spectrum of ZCVI 4 -2 and fluorescence emission spectrum of BSA were measured under pH from 2.13 to 11.76 to estimate the binding sites under different pH.
According to the Förster theory, the energy transfer efficiency E is defined as following Eq. 3 13, 18) :
Here F 0 and F is the fluorescence intensity of donor in the absence and presence of equal amount of accepter (ZCVI 4 -2) respectively, r is the distance between the donor (Trp 212 of BSA) and the acceptor (ZCVI 4 -2), R 0 is the Förster distance (R 0 ), which is the critical energy-transfer distance and can be calculated using Eq. 4 13, 19) :
Where K 2 is the spatial orientation factor of the dipole, N the refractive index of the medium, F the fluorescence quantum yield of the donor, and J is the overlap integral of the fluorescence emission spectrum of the donor and the absorption spectrum of the acceptor was given by Eq. 5 13, 19) :
Here F(l) is the fluorescence intensity of the fluorescence donor at wavelength l and e(l) is the molar absorptivity of the acceptor at wavelength l. F(l) and e(l) were determined by analysis of fluorescence spectroscopy and ultraviolet spectroscopy using OriginPro 7.5 software.
Preparation of ZCVI 4 -2 BSA-Bound Nanocomplexes Five milligrams per milliliters BSA solution was prepared by dissolving BSA in 50 mmol/l phosphate buffer solution at pH 6.8. ZCVI 4 -2 stock ethanolic solution (1.06 mg/ml) was then added to BSA solution (4°C) at a constant rate of 0.1 ml/min to obtain nanocomplexes (C BSA ϭ16 mg/ml, C D ϭ5.56 mg/ml). The particle size analysis was performed by photon correlation spectroscopy (PCS) using a Zetasizer 3000 (Malvern Instruments, Malvern, U.K.). Each sample was measured at 25°C in triplicate. PCS yields the volume weighted mean particle size and the polydispersity index (PI) of the liquid nanocomplexes.
Preparation of BSA-Loaded ZCVI 4 -2 Nanocomplexes with FreezeDrying Protectant Based on the preliminary screening, the combination of 3% mannitol and 4% sucrose was added to BSA-loaded ZCVI 4 -2 nanocomplexes as the lyoprotectant to investigate the influence of lyoprotectant on the release of NO from ZCVI 4 -2.
Fourier Transform-Infrared (FT-IR) Study The solid nanocomplex product was obtained by freeze-drying the binary solution of BSA (0.5 mg/ml) and ZCVI 4 -2 (0.1 mg/ml). The physical mixture was gained by milling equal amount of BSA and ZCVI 4 -2. Infrared spectra of all samples were recorded on a Bruker Tensor 27 Fourier transform infrared spectrometer (Bruker Optics Inc., Germany).
Nitric Oxide Measurement in Vitro The NO measurement was performed to investigate the potential retarding effect of BSA binding on the NO releasing of ZCVI 4 -2 by comparison with ZCVI 4 -2 solution. ZCVI 4 -2 solution was prepared in 0.2% Solutol HS-15, using 50 mmol/l phosphate buffer solution (pH 6.8) containing 5% ethanol as solvent. Reconstituted 
nanocomplex was prepared by reconstitute the lyophilized product in 50 mmol/l phosphate buffer solution (pH 6.8) to evaluate the effect of lyophilization on the NO releasing. The control group of each sample contained all the components except for the drug. The concentration of ZCVI 4 -2 in each sample was 0.1 mg/ml, and ethanol was 5%. The concentration of BSA in BSA contained samples was 5 mg/ml. The characteristics of NO release were studied by using the Griess reaction. [20] [21] [22] [23] Briefly, 5 mmol/l L-cysteine was dissolved in all the samples, and the samples immediately were put into the oven set at 37°C for 30 min. Two milliliters aliquots of each sample was mixed with 0.5 ml aliquots of Griess reagent (4% sulphanilamide; 0.4% N-naphtylethylendiamine dihydrochloride; 10% H 3 PO 4 , w/v) every other 30 to 120 min and incubated at room temperature for 10 min to form an azo-dye. Absorbance was monitored at 540 nm using a UV spectrophotometer and the amount of NO was quantified with NaNO 2 as a standard (the calibration curve was linear over the concentrations range from 0.12 to 1.6 mg/ml (rϭ0.9999)). The capacity to release NO was expressed as the concentration of NO 2Ϫ .
Results and Discussion
The Influence of Temperature on the Quenching of Intrinsic Fluorescence of BSA by ZCVI 4 -2 Fluorescence quenching spectra of BSA solutions (in pH 3.0 and pH 6.8) changed with temperature (Fig. 2) . The addition of drug generally had a quenching effect on BSA fluorescence, which was seen in the whole temperature range investigated when pH was 6.8 and at 4°C and 15°C when pH was 3.0. Nevertheless, at pH 3.0 (22, 30°C), the BSA fluorescence spectrum was sensitized following the addition of drug.
The fluorescence data of samples at different temperatures were analyzed by Stern-Volmer equation, and the Scatchard equation, the results were listed in Table 1 .
The correlation coefficients were larger than 0.90, indicating that the interaction between ZCVI 4 -2 and BSA agreed well with the Stern-Volmer equation and binding equation. A linear Stern-Volmer plot is generally indicative of a single class of fluorophores in a protein, all equally accessibly to the quencher, which also means the presence of only one quenching mechanism (dynamic or static). 10) As presented in Table 1 , at pH 6.8, a negative dependence of K q on temperature was observed in the quenching of BSA fluorescence by ZCVI 4 -2, and K q Ͼ2.0ϫ10 10 l · mol Ϫ1 · s Ϫ1 (the maximum dynamic collision quenching constant of various kinds of quenchers for biopolymers fluorescence), it can be concluded that the nature of quenching is not dynamic but more likely static.
At both pH ( ).
8) The result suggests the quenching mechanism is static. It was found that both the binding constant K b and 'n' decreased with the increase in temperature, resulting in reduction of the stability of the ZCVI 4 -2/BSA complexes. Therefore low temperature is preferred for ZCVI 4 -2/BSA binding.
Types of Interaction Force between ZCVI 4 -2 and BSA Considering the dependence of binding constant on temperature, a thermodynamic process was considered to be responsible for the formation of the nanocomplexes. Therefore, the temperature-dependent thermodynamic parameters were analyzed in order to further characterize the interacting forces between ZCVI 4 -2 and BSA. The interaction forces between a small molecule and macromolecule generally include hydrogen bonding, van der Waals forces, electrostatic forces and hydrophobic interaction forces. The characteristic signs of the thermodynamic parameters were reported to be associated with the various individual kinds of interaction forces between a small molecule and macromolecule (BSA). 24) It was also concluded that the only contributions to positive entropy and enthalpy changes arise from ionic and hydrophobic interactions and the only sources of negative enthalpy and entropy changes arise from van der Waals and hydrogenbond in low dielectric media. The thermodynamic parameters were evaluated using Van't Hoff equation, 12, 17) The results obtained are shown in Table 2 .
The negative values of DG reveal that the interaction process is spontaneous. A negative DH value indicates an exothermic process, and low temperature is helpful for the binding process. In this case, high dielectric media aqueous buffers were used, so the interaction forces between ZCVI 4 -2 and BSA were van der Waals forces.
The Effect of Temperature on the Stability of the ZCVI 4 -2/BSA Nanocomplexes Fluorescence strength of BSA decreased with the increase of temperature by about 29% (0 mg/ml), 22% (20 mg/ml), 17% (40 mg/ml), 9% (60 mg/ml) at pH 3.0, and about 16% (0 mg/ml), 15% (20 mg/ml), 10% (40 mg/ml), 5% (60 mg/ml) at pH 6.8 (Fig.  2) . With the increase of ZCVI 4 -2 concentration, BSA fluorescence became less dependent on temperature, the stability of the ZCVI 4 -2/BSA nanocomplexes increased. Since the main factor in temperature-related denaturation is the breaking of the hydrogen bonds, the improved thermo-stability may stem from the hydrogen bonds formed between ZCVI 4 -2 and the -NH 2 or OH groups in BSA. Moreover, the lack of dependence on temperature at higher ZCVI 4 -2/BSA molar ratio leads us to hypothesize that there are additional stabilization factors between the ZCVI 4 -2 and BSA, such as van der Waals forces. 25, 26) When comparing the stability of the nanocomplex at two given pH values, we found that the complex showed less temperature dependence at pH 6.8 than that at pH 3.0, thus the nanocomplex was more stable at pH 6.8. This could be explained by the conformational change from pH 6.8 to 3.0, which would be further discussed in the following text. At neutral pH, the macromolecule BSA was tightly folded. While at lower pH, it became only loosely connected, and was more sensitive to the variation of the temperature.
Effect of ZCVI 4 -2 Concentration on the Quenching of Intrinsic Fluorescence of BSA under a Series of pHs
With the increase of ZCVI 4 -2 concentration, the fluorescence quenching of BSA increased in the pH ranges investigated, meanwhile, a blue shift happened to the wavelength of maximum emission (Fig. 3) . Except for samples at pH 3.15, a blue shift (6-10 nm) was observed in the maximum emission wavelength of the rest samples. Measuring the peak emission shift is a commonly used method to study the environment of tryptophan. The shift in the peak of emission corresponds to the changes of the polarity around chromophore molecule. The blue shift indicated a decrease in polarity around the tryptophan residues and an increased hydrophobicity. 11, 26) K b and 'n' were calculated using the Binding equation, Eq. 2, and the results are listed in Table 3 . The correlation coefficients were larger than 0.90, indicating that the interaction between ZCVI 4 -2 and BSA agreed well with the site binding model (Eq. 2). Both K b and 'n' reach a maximum at pH 8.78, the second largest value occurred at pH 5.08.
With the increase of pH, several transitions appeared for serum albumins: acid-leaded expansion to fastmigrating at pH 2.5-3.5 (expanded-F), fastmigrating to normal at pH 3.5-4.5 (F-N) and normal to base at pH 6.5-8.5 (N-B) . [27] [28] [29] Generally, under neutral pH, two spherical parts of the BSA were closely combined. When pH is lowered, the two parts become loosely connected, 28) helical structure under the neutral pH transformed to random coil structure under low pH.
In the pH range of 2.0-3.5, BSA solution is in 'expanded' form. The tryptophan residues transferred into a more hydrophobic environment of the BSA molecule, meanwhile, the hydrophilicity of the whole BSA molecule increased, 30) which was coincide with the following results. With the decrease of pH from neutral to pH 2 and pH 3, the wavelength of maximum emission both decreased from 338 to 328 nm, resulting in a blue shift of 10 nm (Fig. 4) , which indicated that the polarity around the tryptophan residues was decreased and the hydrophobicity was increased.
11,31)
The hydrophobic region where tryptophan residues located was the very location ZCVI 4 -2 bound to. When BSA was in the 'expanded' form, there was more hindrance for ZCVI 4 -2 to reach the binding position for it was more deeply buried under this pH range. Nevertheless, the ZCVI 4 -2/BSA nanocomplexes showed superior solubility under this pH range, because of the increase of the hydrophilicity of the whole BSA molecule. The 'K b ' and 'n' of samples under pH 2.13 and pH 3.15 were relatively low, as shown in Table 3 , and more ZCVI 4 -2 can be solubilized by BSA solution in this pH range than at other pHs (data not shown), which coincides with the theory in literatures. 11, 30, 31) Relatively high 'K b ' and 'n' were observed as shown in Table 3 when BSA was in native or 'N' form (about pH 5.0-7.0). 28) In this pH range, more tryptophan residues were exposed to a hydrophilic environment, which made it easier for ZCVI 4 -2 to reach the binding site.
The maximum 'K b ' and 'n' values were obtained under pH 8.78. When the pH value is above 8.0, the BSA molecule undergoes expansion and the conformation changes to the basic form. [31] [32] [33] It was reported that the N-B transition causes strengthening of ligand binding to subdomain IIB (where the tryptophan residues located) 27, 29, 32, 34) which was also demonstrated by 'K b ' and 'n' values in Table 3 . Above pH 8, all basic groups become deprotonated and all carboxyl groups become negatively charged, thus amino acids deprotonated. The breaking of salt bridges between domain I and domain III also contributes to the phenomenon. [28] [29] [30] 35) Compared to 'N' form, the fluctuations of the main chain of the 'B' form are increased, the thermal stabilities were greatly reduced. 29, 34, 35) This might account for the fact that ZCVI 4 -2 did not exhibit high solubility in BSA solution under alkaline pH (data were not provided).
The Binding Site According to Förster's non-radiative energy transfer theory, [36] [37] [38] the energy transfer would happen under the following conditions 39) : (i) the donor(Trp 212 of BSA) can produce fluorescence light, (ii) the fluorescence emission spectrum of the donor and UV absorption spectrum of the acceptor (ZCVI 4 -2) have enough overlap and (iii) in all case, the distance between the donor and the acceptor is at least 3.63 nm, and up to 4.24 nm.
18) The fluorescence quenching of BSA after binding with ZCVI 4 -2 indicated that the energy transfer between ZCVI 4 -2 and BSA had occurred. The overlap of the UV absorption spectrum of ZCVI 4 -2 with the fluorescence emission spectrum of BSA is shown in Fig. 5 . The distance (r) between the donor (Trp 212 of BSA) and the acceptor (ZCVI 4 -2) can be calculated using Eqs. 3-5 and the results were presented in Table 4 .
The distance between ZCVI 4 -2 and the Trp 212 residue (r) was around 3.83 nm in average, and it was little influenced by the pH change. Therefore, it can be concluded that, ZCVI 4 -2 was buried in the hydrophobic pocket in subdomain IIB of BSA, where the Trp 212 residue located. And the exact binding site was about 3.83 nm from Trp 212 .
Analysis of BSA Conformation after ZCVI 4 -2 Binding
Although it was found out that it was the binding of ZCVI 4 -2 738 Vol. 59, No. 6 Fig. 4 . The Fluorescence Spectra when C BSA ϭ0.5 mg/ml, C D ϭ0 mg/ml, pHϭ2. to BSA that caused the fluorescence quenching of BSA, it is still unclear whether the binding affects the conformation and/or the microenvironment of BSA. To further verify the binding of ZCVI 4 -2 to BSA and to explore the structural change of BSA after the addition of ZCVI 4 -2, FT-IR and the synchronous fluorescence spectra of BSA with various amounts of ZCVI 4 -2 were measured (Fig. 6 ).
In the synchronous spectra, the sensitivity associated with fluorescence is maintained, while offers several advantages: spectral simplification, spectral bandwidth reduction and avoiding different disturbing effects. [39] [40] [41] The intrinsic fluorescence of albumins results from the tryptophan and tyrosine residues, and the normal emission spectra of tryptophan and tyrosine residues are overlap, while the synchronous fluorescence spectra is able to distinguish them. [42] [43] [44] When the Dl between excitation wavelength and emission wavelength is fixed at 15 or 60 nm, the synchronous fluorescence will provide information on the microenvironment of tyrosine residues or tryptophan residues respectively. 43, 44) As can be seen from Fig. 6 , after the addition of ZCVI 4 -2, a stronger fluorescence quenching effect of tryptophan residues (Fig. 6b, d ) is observed compared with that of the tyrosine residues (Figs. 6a, c) . This difference indicated that the binding site of ZCVI 4 -2 is more close to tryptophan residues. BSA consists of 582 amino acid residues forming a single polypeptide with well-known sequence, which contains three homologous a-helices domains (i-iii). Each domain is divided into two sub-domains (A and B). The adherence of two sub-domains with their grooves towards each other forms a domain, and three of such domains make up an albumin molecule. 45, 46) BSA has two tryptophan residues (Trp  135 and  Trp   214 ) located in subdomains IA and IIA, respectively. 43, 47) A large hydrophobic cavity is present in the IIA sub-domain, and a wide variety of arrangements can take place in this sub-domain. Trp214 is deeply buried in sub-domain IIA where the highly hydrophobic molecule ZCVI 4 -2 can better penetrate, whereas Trp 135 is located in sub-domain IA which is more exposed to a hydrophilic environment. Therefore, it can be inferred that the primary binding target of ZCVI 4 -2 is sub-domain IIA of BSA where Trp 214 is located. This conclusion is in accordance with the results on the previous part. Moreover, remarkable red shift of maximum emission wavelength of tryptophan residue and the tyrosine residue were observed upon the addition of ZCVI 4 -2, That red shift indicates that the conformation of BSA is changed and tryptophan residues are placed in a more hydrophilic environment, resulting in a increase of polarity in the fluorophore environment, and more exposed to the aqueous environment. 43, 44) Moreover, following the addition of ZCVI 4 -2, fluorescence quenching effect of tryptophan residues (Figs. 6b, d ) and tyrosine residues (Figs. 6a, c) are both stronger in pH 6.8 than that of in pH 3.0, also showing that binding effect of ZCVI 4 -2 to tryptophan residues and tryptophan residues of BSA in pH 6.8 is stronger than that in pH 3.0, then to indicate that the environment of pH 6.8 is more helpful for the binding course. Figure 7 showed the FT-IR spectra of the physical mixture and the nanocomplex of ZCVI 4 -2 and BSA. Usually the amide I band occurs in the region of 1600-1700 cm Ϫ1 and amide II band occurs near 1548 cm
Ϫ1
. Amide I band is more sensitive to the protein conformation changes than amide II. 48, 49) Figure Shown as the arrow, from up to down: C D ϭ0 mg/ml; 20 mg/ml; 40 mg/ml; 60 mg/ml; 80 mg/ml; 100 mg/ml. spectively. A difference of 5 nm was observed between the physical mixture and the nanocomplex. The shift of the amide II was negligible (less than 1 nm). Bases on the results, we proposed that the secondary and tertiary structure of BSA were affected by the binding of ZCVI 4 -2 to BSA. The Characteristics of Nitric Oxide Release To evaluate nitric oxide release from ZCVI 4 -2 in different forms, Griess Reagent Method was applied. Each of these experiments was performed in triplicate. The NO release profiles were shown in Fig. 8 and the average release rate was calculated and listed in Table 5 . The difference factor ( f 1 ) and similarity factor ( f 2 ) were used to compare the release profiles. The similarity factor has been adopted by the Center for Drug Evaluation and Research (FDA) and Human Medicines Evaluation Unit of European Agency for the Evaluation of Medicinal Products (EMEA), as a criterion for the assessment of the similarity between two release profiles. Two profiles would be considered similar if f 1 value is lower than 15 (0-15) and f 2 value is higher than 50 (50-100).
50) The f 1 value and f 2 value were listed in Table 5 . (6) (7) The results showed that the NO release was significantly retarded when ZCVI 4 -2 was in a nanocomplex form (sample B-D in the Table 5 , Fig. 8 ) compared to the solution form (sample A in Table 5 , Fig. 8 ). The NO was completely released within 310 min in the solution and 700 min in the nanocomplex form. Correspondently, the rate of NO release from solution was much faster than from nanocomplex ( Table 5 ). The P (t-test), f 1 and f 2 values showed that there was significant difference in NO release between the solution sample (A) and the nanocomplex samples (B-D), but the difference among the nanocomplex samples (B-D) was not significant. The increase of particle size in aqueous environment and during lyophilization had no significant effect on the release of NO (Table 5 ). These demonstrated that the ZCVI 4 -2/BSA nanocomplexes were suitable for the sustained release of NO, and consequently had the potential to reduce the toxicity of ZCVI 4 -2. As mentioned previously, ZCVI 4 -2 was buried in the hydrophobic region of the BSA when the nanocomplexes formed. BSA was a highly hydrophilic macromolecule, while ZCVI 4 -2 was a highly hydrophobic small molecule. When the latter was inserted into the hydrophilic pocket of the former, the hydrophobicity of the resulting complex fell between the two of them. The mechanism of NO release from furoxan groups was the nucleophilic attack of RS Ϫ on furoxans. 6, 8) Here, L-cysteine acted as a nucleophilic attacker, the NO release occurred only when L-cysteine reached the furoxan group of ZCVI 4 -2. The formation of nanocomplexes played an important role in hindering the L-cysteine from reaching the group, thus delaying the release of NO from ZCVI 4 -2.
Conclusion
By investigating the interaction characteristics between BSA and ZCVI 4 -2, the key preparation parameters of ZCVI 4 - 2/BSA nanocomplexes were determined in the study. At suitable temperature and pH, the spontaneous interaction was in favor of the formation of nanocomplex, where ZCVI 4 -2 was buried in the hydrophobic pocket in subdomain IIB of BSA and the exact binding site was about 3.83 nm from Trp 212 . The BSA bound formation of nanocomplex may be used as a novel and template approach to sustain the release of NO from the serials of nitric oxide-releasing derivatives of oleanolic acid, which have the similar low solubility and NO release properties as ZCVI 4 -2.
1)
